DEA Reschedules Marijuana-Based Drug Epidiolex

This article originally appeared here.
Share this content:
Epidiolex is approved to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.
Epidiolex is approved to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.

GW Pharmaceuticals announced that the US Drug Enforcement Administration (DEA) has rescheduled Epidiolex (cannabidiol) Oral Solution to a Schedule V agent, the lowest restriction classification. 

Epidiolex Oral Solution was approved in June 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients aged ≥2 years. It contains the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol, a type of cannabinoid that does not produce the high associated with marijuana. 

Drugs with a Schedule V classification have proven medical use and low abuse potential. The DEA's decision was supported by non-clinical and clinical data that assessed the potential for abuse with Epidiolex. Vimpat (lacosamide), Briviact (brivaracetam), and Lyrica (pregabalin) are other anti-epileptic drugs in the Schedule V group. Other cannabidiol preparations that are not approved by the Food and Drug Administration (FDA) are still classified within Schedule I. 

Epidiolex Oral Solution will be available as a 100mg/mL strength, strawberry-flavored solution. The Company stated that the product is expected to launch within the next 6 weeks. 

For more information call (833) 424-6724 or visit Epidiolex.com

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters



CME Focus